Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: A brief communication from the New York Phase II consortium

D. Yi Shin Kuo, Patrick Timmins, Stephanie V. Blank, Abbie L. Fields, Gary L. Goldberg, Anthony Murgo, Paul Christos, Scott Wadler, Carolyn D. Runowicz

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

Objective. To define the efficacy of thalidomide on the overall survival of patients with metastatic recurrent gynecologic sarcomas. Patients and methods. All patients with sarcoma or carcinosarcoma of gynecologic origin and documented recurrence or persistence of disease after appropriate surgery, radiation therapy and/or chemotherapy were recruited to the study. All patients were ambulatory and had measurable disease that could be documented on CT scan. Patients were started on 200 mg/day of thalidomide orally every night and escalated by 100-200 mg every 7 to 14 days. The length of the treatment was separated into 2 cycles with the first 84 days defined as the first cycle and the next 56 days as the second cycle. Common Toxicity Criteria were used to record toxicities. Because thalidomide was postulated to induce cytostasis, the end-points were progression-free and overall survival in this mixed group of patients. Results. Seventeen patients were enrolled. The drug was not well tolerated because of constipation, fatigue, worsening performance status, drowsiness and sleepiness. The total dosage of medication given to each patient ranged from 3200 mg to 40,500 mg. The maximum dosage reached in each patient ranged from 300 mg to 750 mg, with the total time of treatment ranging from 13 to 99 days. All patients had progression of disease with a median progression-free survival time of 1.84 months (CI 1.54-2.79 months) and a median overall survival of 6.64 months. Discussion. Thalidomide has no activity in patients with advanced or recurrent gynecologic sarcomas and was not well-tolerated. The overall survival was <7 months. The progression-free survival was <3 months, and, since the therapy was not tolerated well, we unanimously decided to close the study at this point. Despite the poor result, we still believe in the strategy of anti-angiogenesis and will continue to pursue other potential treatment options using the same concept.

Original languageEnglish (US)
Pages (from-to)160-165
Number of pages6
JournalGynecologic Oncology
Volume100
Issue number1
DOIs
StatePublished - Jan 1 2006

Keywords

  • Advanced disease
  • Gynecologic sarcoma
  • Recurrence
  • Thalidomide

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: A brief communication from the New York Phase II consortium'. Together they form a unique fingerprint.

Cite this